A2 Biotherapeutics Competitors and Similar CompaniesClear all
A2 Biotherapeutics's competitors and similar companies include Gamida Cell, VECT-HORUS, Turnstone Biologics and Innate Pharma.
 A2 Biotherapeutics A2 Biotherapeutics is a biotechnology company that develops cell therapies for cancer patients. |  Gamida Cell Gamida Cell develops stem cell therapy technologies and products for the treatment of blood cancers, autoimmune and metabolic diseases. |  VECT-HORUS VECT-HORUS is a biotech company that develops peptide-based vectors to facilitate the delivery of drugs or imaging agents into the brain and to tumors. |  Innate Pharma Innate Pharma is a clinical-stage biotechnology company with a focus on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. | ||
Founding Date | Founding Date 2018 | Founding Date 1998 | Founding Date 2005 | Founding Date 2015 | Founding Date 1999 |
Type | Type Private | Type Public | Type Private | Type Public | Type Public |
Tags | |||||
Locations | Locations Agoura Hills, US HQ | Locations Boston, US HQ Jerusalem, IL | Locations Marseille, FR HQ | Locations San Diego, US HQ Ottawa, CA | Locations Marseille, FR HQ Rockville, US |
Employees | Employees 1255% decrease | Employees 143175% increase | Employees 512% increase | Employees 112 | Employees 181 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 4.3 m | Valuation ($) N/A | Valuation ($) 11.6 m | Valuation ($) 148.6 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $1.8m (FY, 2023) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) €2.8m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $1.5m (FY, 2023) | Cost of goods N/A | Cost of goods N/A | Cost of goods €266k (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit $330k (FY, 2023) | Gross profit N/A | Gross profit N/A | Gross profit €8.7m (FY, 2025) |
Net income | Net income N/A | Net income ($63m) (FY, 2023) | Net income N/A | Net income ($70.8m) (FY, 2024) | Net income (€49.2m) (FY, 2025) |
Funding | |||||
Latest funding round | Latest funding round $ 71.5m (over 5 years ago) | Latest funding round N/A | Latest funding round $ 14.5m (over 5 years ago) | Latest funding round N/A | Latest funding round N/A |
Total funding raised | Total funding raised $ 128.5m | Total funding raised $ 128.3m | Total funding raised $ 29.4m | Total funding raised N/A | Total funding raised $ 94.1m |
For sources of this data, please see the company profile
View Company Profiles
Gamida Cell
HQ
Boston, US
Employees
143
Gamida Cell develops stem cell therapy technologies and products for the treatment of blood cancers, autoimmune and metabolic diseases.
View companyVECT-HORUS
HQ
Marseille, FR
Employees
51↑ 2% increase
VECT-HORUS is a biotech company that develops peptide-based vectors to facilitate the delivery of drugs or imaging agents into the brain and to tumors.
View company
Turnstone Biologics
HQ
San Diego, US
Employees
112
Turnstone Biologics is an immuno-oncology company.
View companyInnate Pharma
HQ
Marseille, FR
Employees
181
Innate Pharma is a clinical-stage biotechnology company with a focus on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients.
View company